Dm Disease-A-MonthPub Date : 2025-05-01DOI: 10.1016/j.disamonth.2025.101863
Neel Vora , Parth Patel , Mohammed Dheyaa Marsool Marsool , Ali Dheyaa Marsool Marsool , Rayyan Sunasra , Parva Ladani , Shefali Pati , Dhruvi Khoont , Priyadarshi Prajjwal , Raunak Ranjan
{"title":"Atypical Alzheimer's dementia: Addressing the subtypes, epidemiology, atypical presentations, diagnostic biomarkers, and treatment updates","authors":"Neel Vora , Parth Patel , Mohammed Dheyaa Marsool Marsool , Ali Dheyaa Marsool Marsool , Rayyan Sunasra , Parva Ladani , Shefali Pati , Dhruvi Khoont , Priyadarshi Prajjwal , Raunak Ranjan","doi":"10.1016/j.disamonth.2025.101863","DOIUrl":"10.1016/j.disamonth.2025.101863","url":null,"abstract":"<div><div>Alzheimer's disease is a progressive neurodegenerative disorder that primarily affects the elderly population; and is characterized by the gradual loss of memory, cognition, and ability to carry out daily activities. However, a growing body of research indicates that there exists a subtype of Alzheimer's disease known as Atypical Alzheimer's disease. Atypical Alzheimer's disease is a rare form of dementia that differs from the typical presentation of Alzheimer's disease, such as variations in the age of onset, distribution of brain pathology, and clinical symptoms. The patients affected have a younger age of onset and have predominantly visual, language, executive function, motor, and behavioral dysfunction. The diagnosis requires a comprehensive neurological evaluation with specific attention to cognitive and behavioral changes while ruling out other potential causes of dementia. Emerging biomarkers including CSF profiles, amyloid and tau PET imaging, and advanced neuroimaging techniques offer promising avenues for improving diagnostic accuracy and understanding disease mechanisms. In this article, we focus on atypical presentations seen in the posterior cortical variant, frontal variant, progressive aphasic variant, corticobasal syndrome and look at the specific biomarkers used in the diagnosis of each variant along with focusing on the treatment of the disease. We also aim to provide an understanding of Atypical Alzheimer's disease, its clinical features, the biomarkers helping in diagnosing the disease, the current treatment guidelines, and the current scientific advancements in the field.</div></div>","PeriodicalId":51017,"journal":{"name":"Dm Disease-A-Month","volume":"71 5","pages":"Article 101863"},"PeriodicalIF":3.8,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143081332","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Dm Disease-A-MonthPub Date : 2025-04-01DOI: 10.1016/j.disamonth.2024.101848
Anna Gaddy MD , Mohamed Elrggal MD , Hector Madariaga MD , Adam Kelly MD , Edgar Lerma MD , Gates B Colbert MD
{"title":"Diabetic Kidney Disease","authors":"Anna Gaddy MD , Mohamed Elrggal MD , Hector Madariaga MD , Adam Kelly MD , Edgar Lerma MD , Gates B Colbert MD","doi":"10.1016/j.disamonth.2024.101848","DOIUrl":"10.1016/j.disamonth.2024.101848","url":null,"abstract":"<div><div>Diabetic kidney disease is a leading cause of kidney failure worldwide and is easily detectable with screening examination. Diabetes causes hyperfiltration and activation of the renin-angiotensin aldosterone system by hemodynamic changes within the nephron, which perpetuates damaging physiology. Diagnosis is often clinical after detection of heavy proteinuria in a patient with diabetes,but can be confirmed by observation of histologic stages on kidney biopsy. Mainstays of treatment include angiotensin conversion or receptor blockade, mineralocorticoid receptor blockade, and tight glucose control. Newer agents favored in diabetic kidney disease are sodium glucose-cotransporters and glucagon-like peptide 1 receptor agonists, both for glycemic control and for various methods of reversing damaging physiology.</div></div>","PeriodicalId":51017,"journal":{"name":"Dm Disease-A-Month","volume":"71 4","pages":"Article 101848"},"PeriodicalIF":3.8,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142928722","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
